

U.S. Patent Appl. No. 09/840,872
Attorney Docket No. 037003-0280609

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

In re PATENT APPLICATION OF

Confirmation No. 4921

Antonio J. GRILLO-LOPEZ et al.

Group Art Unit: 1642

Application Serial No. 09/840,872

Examiner: Gary B. Nickol

Filed: April 25, 2001

Title: INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR TREATMENT OF
CENTRAL NERVOUS SYSTEM LYMPHOMAS

JAN 12 2006

* * * * *

AMENDMENT PURSUANT TO 37 C.F.R. 1.111

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is in response to the official action [non-final rejection] dated July 12, 2005, wherein the claims were rejected under 35 U.S.C. § 102(b) and § 103(a) and under the judicially created doctrine of obviousness-type double patenting. A declaration pursuant to 37 CFR 1.132 and Form PTO-1449, which identifies references discussed in the declaration, are submitted herewith. Also is submitted is a petition for a three-month extension of time and payment of the requisite fee. The enclosed petition further authorizes payment of any additionally required fees by the deposit account identified therein.

BEST AVAILABLE COPY